Federal Circuit Reverses Priority In Claritin Battle
In a protracted patent interference case, a pharmaceutical company hoping to trump its rival's patent for making Claritin's active ingredient has lost once again at the U.S. Court of Appeals for...To view the full article, register now.
Already a subscriber? Click here to view full article